-
Man City whistleblower Pinto to stay under police protection
-
BMW pulls car lease offer from German far-right politician
-
US leads fresh Ukraine peace push with Miami talks
-
Brazil election offers Jair Bolsonaro a shot at revenge
-
Verstappen continues resurgence with pole for Singapore sprint
-
Man Utd boss Carrick 'personally' affected by Man City verdict
-
Cuban ration book, symbol of the revolution, gathers dust
-
Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to $10–$11 Million and Reaffirms $400–$460 Million Fiscal 2027 Outlook
-
Stocks advance, oil retreats as Trump rules out pre-vote Iran attack
-
Red Bull's Verstappen takes pole position for Singapore GP sprint race
-
Man City case causing 'uncertainty' for whole Premier League, says Iraola
-
Chelsea star Palmer 'committed' to England insists Alonso
-
Talks with Iran can only succeed without threats, president says
-
OpenAI denies firing researchers over AI safety warnings
-
Home hope Zheng sets up Mertens clash in China Open semis
-
Turkey warns opposition, press over investment fund crisis
-
Lombardia promises gripping end to season in Pogacar absence
-
Hurricane Isaias now major storm as it heads to US Gulf Coast
-
Barca skipper Raphinha out against Getafe and Galatasaray
-
Djokovic crashes out of Shanghai Masters in his first match
-
MEXC and Payward Highlight Collaboration as Crypto and TradFi Converge at TOKEN2049
-
EU says Turkey's crackdown on rights hampers membership bid
-
EU states agree beefed-up European financial markets watchdog
-
Two Renoir paintings stolen in France recovered: mayor
-
Eritrea, Ethiopia trade barbs as Tigray rebels retreat
-
German leader outraged at Schroeder birthday visit to Putin
-
Kompany 'proud' of Man City success despite guilty verdict
-
Stocks up, oil retreats as Trump rules out pre-vote Iran attack
-
Man City will win appeal over financial charges, says Maresca
-
South African judge Navi Pillay wins Nobel Peace Prize
-
Fernandez logs record lap at Indonesia MotoGP practice
-
'I completely trust the club,' says Man City boss Maresca
-
Navi Pillay: S.Africa's global rights activist and Nobel winner
-
'10 out of 10' Quintana reminisces over dream Vuelta win
-
Ufunded Launches “Spotlight” Series, Documenting the Minds Shaping Modern Trading
-
Maddinson given shock recall but fails to score
-
Russell goes fastest in practice for smoggy Singapore GP
-
Navi Pillay, South African rights champion, wins Nobel Peace Prize
-
For exiled Russian director Zvyagintsev, triumph without belonging
-
Saudi Arabia says three killed at airport as Yemen war expands
-
Home hope Zheng storms into China Open semi-finals
-
Everton's US owners mull sale of club two years after takeover
-
Zverev churns out win in Shanghai Masters opener
-
Ukraine takes Russia fight to 'scorching sands' of Sahel
-
Hurricane Isaias strengthens en route to US Gulf Coast
-
Chinese AI tool pulled to prevent 'misuse' after South Korea hacks
-
US activists deploy poll volunteers over Trump intimidation fears
-
Asian stocks mostly up as traders weigh AI, oil dips after surge
-
Saint Laurent designer Vaccarello leaves after glittering decade
-
Walking through flames: orangutans rescued in Indonesia fires
DATATRAK Standalone eConsent Accelerates Clinical Trials
eConsent solution deploys in under four weeks, integrates with any EDC, and delivers affordable, patient‑centric digital consent
AUSTIN, TX / ACCESS Newswire / February 26, 2026 / DATATRAK International, Inc.'s (OTC:DTRK) DATATRAK Powered by Fountayn unified eClinical, eSource, and decentralized clinical trial (DCT) platform, announces the release of its standalone eConsent solution designed to help sponsors, CROs, and sites modernize informed consent while reducing startup timelines and technology costs. The new eConsent offering can be deployed in under four weeks and is available as a lightweight, cost‑effective module or as a fully integrated component of the DATATRAK Powered by Fountayn EDC and DCT ecosystem.
Unlike many eConsent tools that are bundled only within large, expensive ePRO or DCT packages, DATATRAK's standalone eConsent delivers flexible pricing so study teams can implement digital informed consent without paying for an entire ePRO system they do not need. Reasonable, study‑level pricing makes eConsent accessible for a broader range of trials and budgets, including early‑phase, single‑site, and investigator‑initiated studies.
"Study teams want the benefits of modern eConsent-faster startup, better participant understanding, and cleaner documentation-without lengthy implementations or bloated platform costs," said Alex Tabatabai, CEO, DATATRAK. "Our standalone eConsent is purpose‑built to launch quickly, fit into existing study infrastructure, and scale seamlessly when sponsors are ready to expand into DATATRAK EDC, ePRO, RTSM, CTMS, or full decentralized clinical trials."
Fast Startup, IND‑Ready Timelines
The DATATRAK eConsent solution is designed for implementation timelines of under four weeks, allowing study teams to go live in time for IND or ethics approval and first‑patient‑in milestones. Configuration is supported by reusable templates and best‑practice workflows that help streamline approvals and site activation.
Standalone eConsent with Enterprise‑Grade Integration
The eConsent module can be used as a standalone utility and integrated with third‑party infrastructure, including external EDC, RTSM, CTMS, and eTMF systems, or deployed as a native component of DATATRAK EDC. When used with DATATRAK EDC, consent data and enrollment status are seamlessly connected to subject records, randomization, and visit schedules, enabling true end‑to‑end digital trial execution on a single platform.
Key Capabilities Include:
1. Standalone eConsent that integrates with third‑party clinical trial systems or EDC
2. Seamless integration with the consent and enrollment workflow in EDC
3. Support for remote and decentralized clinical trials with patient access from any device
4. Designed for protocol amendments and regulatory workflows
DATATRAK's eConsent simplifies managing protocol amendments and re‑consent, a common pain point for sponsors and sites. Study teams can easily trigger and track re‑consent when protocol changes occur, ensuring every participant is on the correct version and that audit trails remain inspection‑ready.
The system also supports tracking and managing supporting documents such as witness statements, translations, and supplemental information, helping maintain complete, compliant records across sites and regions.
Flexible Patient Engagement and Enrollment Options
To support both site‑based and remote enrollment, the eConsent solution enables sites to invite participants using multiple methods: email links, QR codes patients can scan on their own device, or direct registration by the physician or site staff. Sites can also schedule consent visits prior to trial enrollment, helping ensure participants have adequate time to review materials, ask questions, and complete consent in a controlled, compliant workflow.
When combined with DATATRAK's EDC, ePRO, and eSource capabilities, sponsors can extend the same patient‑centric digital experience beyond consent to ongoing data collection and engagement throughout the study.
About DATATRAK
DATATRAK Powered by Fountayn is transforming healthcare and life sciences through technological innovations by providing a unified, cloud based eClinical and decentralized clinical trial platform that brings together EDC, eSource, ePRO/eCOA, eConsent, RTSM, RBM, Adjudication, Imaging, Safety, Global Oversight and Enterprise Workflow Management, CTMS, eTMF, and DCT tools in a single, configurable environment. With global access from any device and a single‑source data model, DATATRAK helps sponsors, CROs, and sites accelerate study timelines, improve data quality, and reduce operational burden across all phases of clinical research. DATATRAK complies with the highest Quality Assurance standards that are 21 CFR Part 11, GDPR, GCP, HIPAA, and CDISC compliant that are fully validated by our experienced team of software quality engineers. DATATRAK's cloud-based platform is trusted in 83 countries, 6 continents, for over 10,000 clinical trials. DATATRAK is based in Austin, Texas and has team members and data hosting infrastructure in its key service regions of the United States, Europe, and Japan. For more information, visit www.fountayn.com or www.datatrak.com.
Contact: [email protected]
SOURCE: Datatrak International
View the original press release on ACCESS Newswire
P.Smith--AT